Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 TrialBusiness Wire • 02/17/23
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?Investors Business Daily • 02/17/23
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation (AFib) and its SymptomsBusiness Wire • 02/16/23
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaBusiness Wire • 02/13/23
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 StudyBusiness Wire • 02/10/23
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology ConferenceBusiness Wire • 02/03/23
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact SalesZacks Investment Research • 02/02/23
Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 02/02/23
Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings OutlookInvestors Business Daily • 02/02/23
Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops EstimatesBarrons • 02/02/23
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022Business Wire • 02/02/23